HBK Sorce Advisory LLC Makes New Investment in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Share on StockTwits

HBK Sorce Advisory LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,292 shares of the specialty pharmaceutical company’s stock, valued at approximately $324,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Machina Capital S.A.S. acquired a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $29,000. Signaturefd LLC boosted its holdings in Jazz Pharmaceuticals by 56.3% in the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 72 shares in the last quarter. Captrust Financial Advisors boosted its holdings in Jazz Pharmaceuticals by 120.0% in the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 120 shares in the last quarter. Clear Perspective Advisors LLC acquired a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $81,000. Finally, Commonwealth Bank of Australia boosted its holdings in Jazz Pharmaceuticals by 20.5% in the second quarter. Commonwealth Bank of Australia now owns 775 shares of the specialty pharmaceutical company’s stock valued at $110,000 after purchasing an additional 132 shares in the last quarter. Institutional investors and hedge funds own 87.62% of the company’s stock.

In other news, Director Catherine A. Sohn sold 726 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $135.65, for a total transaction of $98,481.90. Following the completion of the sale, the director now owns 9,574 shares in the company, valued at $1,298,713.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

NASDAQ JAZZ traded down $1.10 on Wednesday, reaching $131.81. The stock had a trading volume of 1,149 shares, compared to its average volume of 535,454. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. Jazz Pharmaceuticals PLC has a 12-month low of $113.52 and a 12-month high of $169.82. The business’s 50-day moving average price is $131.18 and its 200 day moving average price is $134.61. The stock has a market cap of $7.32 billion, a P/E ratio of 10.77, a price-to-earnings-growth ratio of 1.59 and a beta of 1.10.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The company had revenue of $534.13 million during the quarter, compared to analysts’ expectations of $507.23 million. During the same quarter in the previous year, the business earned $3.49 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current year.

A number of equities analysts recently issued reports on the company. Barclays upped their price target on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, August 12th. BMO Capital Markets set a $208.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 price target for the company. in a report on Friday, September 13th. Finally, Royal Bank of Canada set a $184.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, July 3rd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $168.43.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What is a Buy-Side Analyst?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MediBloc [QRC20] Trading Down 14.4% Over Last 7 Days
MediBloc [QRC20] Trading Down 14.4% Over Last 7 Days
MineBee  Market Capitalization Achieves $46.30 Million
MineBee Market Capitalization Achieves $46.30 Million
The ChampCoin Trading Up 19.7% This Week
The ChampCoin Trading Up 19.7% This Week
Intellicheck Mobilisa, Inc.  Expected to Post Earnings of -$0.06 Per Share
Intellicheck Mobilisa, Inc. Expected to Post Earnings of -$0.06 Per Share
Joint Ventures  Price Hits $0.0011 on Top Exchanges
Joint Ventures Price Hits $0.0011 on Top Exchanges
Analysts Expect SUMMIT THERAPEU/S  Will Announce Earnings of -$0.23 Per Share
Analysts Expect SUMMIT THERAPEU/S Will Announce Earnings of -$0.23 Per Share


© 2006-2019 Ticker Report